Oncolytics Biotech Inc T.ONC

Trucchio @Wainwright...

[fox7mf]

...maintained Oncy's buy rating and $15 usd target price yesterday. That valuation is what Oncy should be presently trading at. Investors would be peachy with that number if we are indeed in b/o discussions. Alas, shareholder value creation isn't Matt's forte. Cue the apologists....

[jh1970]

This SP is a joke. But why ?

[fox7mf]

Well, SP doesn't matter...or so some insist. Sigilon type buyouts are few and very far between. Some very astute investors on Stocktwits wholeheartedly believe Oncy is currently engaged in negotiations with one of Roche or Merck. They also believe Oncy is negotiating from a position of weakness. Thx Coffey. 

[2O2Ovision]

Hey Fox I can't see who you're arguing with but the Sigilon deal is only 35M upfront and seeing as Lily already owned about 9% only costs them 30M net, with milestone for roughly another 300M net. So yeah their shares jumped from just under 4$ to low 20's on the annoucement but if were talking about such low numbers with ONC, it would be something along the lines of a partnership not a

[Peladawn]

This post has been removed in accordance with Community Policy

[Azzak34]

Hey, none taken:)

[Buckhenry]

I think we need a fireside chat from Matt and a group hug would not hurt either. Cumbiah 

[Azzak34]

It's Kumbaya. 

[13X2413]

Did the fine print say....post consolidation?

[venture009]

If you calculate the market value based on the science there has always been an argument that the share price has been always under valued. The big money has always understood that ONCY never has enough money to ever do much of anything other than keep the lights on. Every dilution is just enough to cover g&a with the hope that successful trial results will once again propel it higher. Now